Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Статья

Non-thermal plasma-induced immunogenic cell death in cancer

Marian KhaliliDivision of Surgery Oncology, Department of Surgery, Drexel University College of Medicine, Philadelphia, PALynsey DanielsDivision of Surgery Oncology, Department of Surgery, Drexel University College of Medicine, Philadelphia, PAAbraham LinCenter for Oncological Research (CORE), University of AntwerpFred C. KrebsDepartment of Microbiology and Immunology, and Institute for Molecular Medicine &. Infectious Disease, Drexel University College of Medicine, Philadelphia, PAAdam E. SnookDepartment of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PASander BekeschusCentre for Innovation Competence (ZIK) plasmatis, Leibniz Institute for Plasma Science and Technology (INP Greifswald), Felix-Hausdorff-Str.2, 17489 Greifswald, GermanyWilbur B. BowneDivision of Surgery Oncology, Department of Surgery, Drexel University College of Medicine, Philadelphia, PAVandana MillerCentre for Innovation Competence (ZIK) plasmatis, Leibniz Institute for Plasma Science and Technology (INP Greifswald), Felix-Hausdorff-Str.2, 17489 Greifswald, Germany
2019en
ABI

Аннотация

Recent advances in biomedical research in cancer immunotherapy have identified the use of an oxidative stress-based approach to treat cancers, which works by inducing immunogenic cell death (ICD) in cancer cells. Since the anti-cancer effects of non-thermal plasma (NTP) are largely attributed to the reactive oxygen and nitrogen species that are delivered to and generated inside the target cancer cells, it is reasonable to postulate that NTP would be an effective modality for ICD induction. NTP treatment of tumors has been shown to destroy cancer cells rapidly and, under specific treatment regimens, this leads to systemic tumor-specific immunity. The translational benefit of NTP for treatment of cancer relies on its ability to enhance the interactions between NTP-exposed tumor cells and local immune cells which initiates subsequent protective immune responses. This review discusses results from recent investigations of NTP application to induce immunogenic cell death in cancer cells. With further optimization of clinical devices and treatment protocols, NTP can become an essential part of the therapeutic armament against cancer.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0